The emerging role of lncRNA MEG3 and MEG3 rs7158663 in hepatocellular carcinoma

Eur Rev Med Pharmacol Sci. 2022 Jan;26(1):11-21. doi: 10.26355/eurrev_202201_27742.

Abstract

Objective: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy in Egypt. Genetic and environmental factors play a role in its development. This study explored the association between the long non-coding RNA (lncRNA) MEG3 rs7158663 polymorphism, MEG3 expression, and the risk of HCC and other clinicopathologic characteristics in an Egyptian population.

Patients and methods: This case-control study included 114 patients with HCC and 110 healthy controls. TaqMan Real-time PCR was used to analyze lncRNA MEG3 rs7158663. Serum MEG3 expression levels were measured using RT-PCR.

Results: The AA, GA+AA, and A alleles were associated with increased risk for HCC (adjusted odds ratio (OR) 11.84%, 95% CI 4.07-34.45, p < 0.0001; adjusted OR 3.18, 95% CI 1.79-5.67, p < 0.0001; and adjusted OR 2.87, 95% CI 1.91-4.34, p < 0.0001, respectively). The mutant genotype and allele were linked to an increased risk in male patients and patients ≥ 50 years old. MEG3 serum expression level was downregulated in HCC patients. The rs7158663 G > A polymorphism and downregulated MEG3 were significantly associated with larger tumor size and advanced disease stage.

Conclusions: MEG3 rs7158663 single nucleotide polymorphisms and downregulated lncRNA MEG3 were associated with HCC risk and may represent diagnostic and bad prognostic factors for HCC patients.

MeSH terms

  • Carcinoma, Hepatocellular* / genetics
  • Case-Control Studies
  • Genetic Predisposition to Disease
  • Humans
  • Liver Neoplasms* / genetics
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • RNA, Long Noncoding* / genetics

Substances

  • MEG3 non-coding RNA, human
  • RNA, Long Noncoding